228 related articles for article (PubMed ID: 32159286)
21. Emicizumab-mediated hemostatic function assessed by thrombin generation assay in an in vitro model of factor VIII-depleted thrombophilia plasma.
Yada K; Ogiwara K; Shimonishi N; Nakajima Y; Soeda T; Kitazawa T; Nogami K
Int J Hematol; 2024 Feb; 119(2):109-118. PubMed ID: 38112996
[TBL] [Abstract][Full Text] [Related]
22. Hemostatic effect of a monoclonal antibody mAb 2021 blocking the interaction between FXa and TFPI in a rabbit hemophilia model.
Hilden I; Lauritzen B; Sørensen BB; Clausen JT; Jespersgaard C; Krogh BO; Bowler AN; Breinholt J; Gruhler A; Svensson LA; Petersen HH; Petersen LC; Balling KW; Hansen L; Hermit MB; Egebjerg T; Friederichsen B; Ezban M; Bjørn SE
Blood; 2012 Jun; 119(24):5871-8. PubMed ID: 22563084
[TBL] [Abstract][Full Text] [Related]
23. Improved hemostasis in hemophilia mice by means of an engineered factor Va mutant.
von Drygalski A; Cramer TJ; Bhat V; Griffin JH; Gale AJ; Mosnier LO
J Thromb Haemost; 2014; 12(3):363-72. PubMed ID: 24818532
[TBL] [Abstract][Full Text] [Related]
24. Novel treatments for hemophilia through rebalancing of the coagulation cascade.
Zhao Y; Weyand AC; Shavit JA
Pediatr Blood Cancer; 2021 May; 68(5):e28934. PubMed ID: 33577709
[TBL] [Abstract][Full Text] [Related]
25. Anti-C1 domain antibodies that accelerate factor VIII clearance contribute to antibody pathogenicity in a murine hemophilia A model.
Batsuli G; Ito J; Mercer R; Baldwin WH; Cox C; Parker ET; Healey JF; Lollar P; Meeks SL
J Thromb Haemost; 2018 Sep; 16(9):1779-1788. PubMed ID: 29981270
[TBL] [Abstract][Full Text] [Related]
26. Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Single Domain Antibodies Are Potent Inhibitors of Low Density Lipoprotein Receptor Degradation.
Weider E; Susan-Resiga D; Essalmani R; Hamelin J; Asselin MC; Nimesh S; Ashraf Y; Wycoff KL; Zhang J; Prat A; Seidah NG
J Biol Chem; 2016 Aug; 291(32):16659-71. PubMed ID: 27284008
[TBL] [Abstract][Full Text] [Related]
27. Aptamer ARC19499 mediates a procoagulant hemostatic effect by inhibiting tissue factor pathway inhibitor.
Waters EK; Genga RM; Schwartz MC; Nelson JA; Schaub RG; Olson KA; Kurz JC; McGinness KE
Blood; 2011 May; 117(20):5514-22. PubMed ID: 21389323
[TBL] [Abstract][Full Text] [Related]
28. Safety and efficacy of an anti-human APC antibody for prophylaxis of congenital factor deficiencies in preclinical models.
Jiang M; Yang F; Jiang Y; Cheng L; Han J; Yi J; Zuo B; Huang L; Ma Z; Li T; Cao LJ; Xia Z; Bai X; Jia C; Yang TTC; Esmon NL; Ruan C; Xia L; Esmon CT; Han Y; Wu D; Xu J
Blood; 2023 Sep; 142(12):1071-1081. PubMed ID: 37294924
[TBL] [Abstract][Full Text] [Related]
29. Human factor IX corrects the bleeding diathesis of mice with hemophilia B.
Kung SH; Hagstrom JN; Cass D; Tai SJ; Lin HF; Stafford DW; High KA
Blood; 1998 Feb; 91(3):784-90. PubMed ID: 9446637
[TBL] [Abstract][Full Text] [Related]
30. Thrombin generation and implications for hemophilia therapies: A narrative review.
Sidonio RF; Hoffman M; Kenet G; Dargaud Y
Res Pract Thromb Haemost; 2023 Jan; 7(1):100018. PubMed ID: 36798897
[TBL] [Abstract][Full Text] [Related]
31. Sustained FVIII expression and phenotypic correction of hemophilia A in neonatal mice using an endothelial-targeted sleeping beauty transposon.
Liu L; Mah C; Fletcher BS
Mol Ther; 2006 May; 13(5):1006-15. PubMed ID: 16464640
[TBL] [Abstract][Full Text] [Related]
32. Factor VIII ectopically targeted to platelets is therapeutic in hemophilia A with high-titer inhibitory antibodies.
Shi Q; Wilcox DA; Fahs SA; Weiler H; Wells CW; Cooley BC; Desai D; Morateck PA; Gorski J; Montgomery RR
J Clin Invest; 2006 Jul; 116(7):1974-82. PubMed ID: 16823491
[TBL] [Abstract][Full Text] [Related]
33. EPCR deficiency or function-blocking antibody protects against joint bleeding-induced pathology in hemophilia mice.
Magisetty J; Pendurthi UR; Esmon CT; Rao LVM
Blood; 2020 Jun; 135(25):2211-2223. PubMed ID: 32294155
[TBL] [Abstract][Full Text] [Related]
34. B Cell Depletion Eliminates FVIII Memory B Cells and Enhances AAV8-coF8 Immune Tolerance Induction When Combined With Rapamycin.
Biswas M; Palaschak B; Kumar SRP; Rana J; Markusic DM
Front Immunol; 2020; 11():1293. PubMed ID: 32670285
[TBL] [Abstract][Full Text] [Related]
35. Targeting protease nexin-1, a natural anticoagulant serpin, to control bleeding and improve hemostasis in hemophilia.
Aymonnier K; Kawecki C; Venisse L; Boulaftali Y; Christophe OD; Lenting PJ; Arocas V; de Raucourt E; Denis CV; Bouton MC
Blood; 2019 Nov; 134(19):1632-1644. PubMed ID: 31383642
[TBL] [Abstract][Full Text] [Related]
36. Activated protein C inhibitor for correction of thrombin generation in hemophilia A blood and plasma1.
Brummel-Ziedins KE; Whelihan MF; Rivard GE; Butenas S
J Thromb Haemost; 2011 Nov; 9(11):2262-7. PubMed ID: 21920012
[TBL] [Abstract][Full Text] [Related]
37. Inhibition of tissue factor pathway inhibitor by the aptamer BAX499 improves clotting of hemophilic blood and plasma.
Gorczyca ME; Nair SC; Jilma B; Priya S; Male C; Reitter S; Knoebl P; Gilbert JC; Schaub RG; Dockal M; McGinness KE; Pabinger I; Srivastava A
J Thromb Haemost; 2012 Aug; 10(8):1581-90. PubMed ID: 22632032
[TBL] [Abstract][Full Text] [Related]
38. The old and new: PCCs, VIIa, and long-lasting clotting factors for hemophilia and other bleeding disorders.
Ragni MV
Hematology Am Soc Hematol Educ Program; 2013; 2013():44-51. PubMed ID: 24319161
[TBL] [Abstract][Full Text] [Related]
39. Phenotypic correction and long-term expression of factor VIII in hemophilic mice by immunotolerization and nonviral gene transfer using the Sleeping Beauty transposon system.
Ohlfest JR; Frandsen JL; Fritz S; Lobitz PD; Perkinson SG; Clark KJ; Nelsestuen G; Key NS; McIvor RS; Hackett PB; Largaespada DA
Blood; 2005 Apr; 105(7):2691-8. PubMed ID: 15576475
[TBL] [Abstract][Full Text] [Related]
40. New therapies using nonfactor products for patients with hemophilia and inhibitors.
Nogami K; Shima M
Blood; 2019 Jan; 133(5):399-406. PubMed ID: 30559263
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
